Alteration of PTFE Surface to Increase Its Blood Compatibility

The aim of this study is to increase the blood compatibility of polytetrafluoroethylene (PTFE), one of the preferred materials for soft-tissue application, by a two-step procedure: first, the surface was activated by hydrogen plasma followed by acrylamide attachment and, secondly, hirudin, a potent...

Full description

Saved in:
Bibliographic Details
Published in:Journal of biomaterials science. Polymer ed. 2011-01, Vol.22 (11), p.1443-1457
Main Authors: Onder, Sakip, Kazmanli, Kursat, Kok, Fatma Nese
Format: Article
Language:English
Subjects:
BLOOD COMPATIBILITY
HIRUDIN
Hirudinea
PLASMA TREATMENT
PTFE
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study is to increase the blood compatibility of polytetrafluoroethylene (PTFE), one of the preferred materials for soft-tissue application, by a two-step procedure: first, the surface was activated by hydrogen plasma followed by acrylamide attachment and, secondly, hirudin, a potent antithrombogenic protein from leeches, was immobilized to the surface. Plasma treatment conditions were optimized and different surfaces were characterized by water contact angle measurements, ATR-FT-IR and X-ray photoelectron spectroscopy (XPS). It was seen that the contact angle of the PTFE decreased from 126° to 55° in optimum conditions. Acrylamide (25% (w/v) in ethanol/acetone (50%, v/v)) was grafted to the surface by the help of argon plasma treatment (1 min, 50 W, 13 Pa). The water contact angle was further decreased to 33° with acrylamide grafting and amide groups, which were subsequently used in protein immobilization, and could be detected both by ATR-FT-IR and XPS analysis. In the second part, hirudin was attached to these amide groups on PTFE surface by an optimized EDC/NHS activation procedure. Then a thrombogenicity test was done to detect hirudin activity. The results showed that there is a significant decrease in the clot formation compared with the untreated PTFE samples and ca. 0.3-0.4 ATU/cm 2 (22-29 ng/cm 2 ) of hirudin was enough to prevent the clot formation. A preliminary study showed that the hirudin immobilized membranes keep their antithrombogenic activity for at least 40 days in 37°C in PBS (0.1 M, pH 7.4). As a result, the blood compatibility of PTFE surfaces was ameliorated by plasma-induced monomer grafting and hirudin immobilization, and an alternative material was obtained to be used in medical applications such as vascular grafts, catheters, etc.
ISSN:0920-5063
1568-5624
DOI:10.1163/092050610X510551